Want to see CH:RO full AI Analyst Report?
RO Stock Chart & Stats
CHF360.00
CHF5.00(1.39%)
At close: 4:00 PM EDT
CHF360.00
CHF5.00(1.39%)
Day’s Range― - ―
52-Week RangeCHF256.40 - CHF383.00
Previous CloseN/A
Volume20.53K
Average Volume (3M)28.08K
Market Cap
CHF281.86B
Enterprise ValueCHF299.83K
Total Cash (Recent Filing)CHF9.73B
Total Debt (Recent Filing)CHF31.80B
Price to Earnings (P/E)23.0
Beta1.32
Next Earnings
Feb 04, 2027EPS Estimate
9.65Next Dividend Ex-DateN/A
Dividend Yield3.01%
Share Statistics
EPS (TTM)15.36
Shares Outstanding106,691,000
10 Day Avg. Volume29,793
30 Day Avg. Volume28,076
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.24
Revenue Forecast (FY)CHF63.15B
Bulls Say, Bears Say
Bulls Say
High Profitability & Cash GenerationRoche's persistently high gross margins and consistent EBIT profile, combined with recurring free cash flow in the low‑double‑digit billions, fund R&D, dividend increases and targeted M&A. This durable cash generation supports reinvestment and cushions cyclical revenue volatility over 2–6 months and beyond.
Robust Late‑stage Pipeline & Regulatory MomentumMultiple priority reviews, breakthrough designations and an elevated Phase III success rate materially raise the probability and speed of approvals. That accelerates commercialization of new assets, diversifies future revenue streams beyond aging brands and improves medium‑term growth visibility for several years.
Diagnostics Recurring Revenues & New Platform LaunchesNew instruments and CE‑marked assays (AXELIOS 1, Elecsys IGRA/Tau) strengthen Roche's installed base and recurring reagent/consumable sales. Durable installed‑base economics in diagnostics support steady consumable volume, service revenue and margin resilience across multi‑year horizons.
Bears Say
China Diagnostics Pricing ReformA structural pricing reform in China reduced Diagnostics sales materially; weaker reimbursement and lower pricing in a large market can permanently compress reagent volumes and margin mix. Recovery depends on policy shifts or volume gains, creating a multi‑quarter headwind to Diagnostics growth and profitability.
Higher Leverage / Net Debt IncreaseA mid‑year net debt increase and sustained gross debt elevate financial leverage (debt/equity ~0.9). Higher leverage reduces optionality for large transformational spending, increases sensitivity to interest and currency moves, and places greater reliance on sustained cash conversion to preserve balance‑sheet flexibility.
LOE And Biosimilar CompetitionLoss‑of‑exclusivity and biosimilar entrants (and existing competitive pressure) are predictable, structural revenue erosions. Expected LOE and observed biosimilar impacts force faster product replacement and higher R&D or BD spend to sustain growth, pressuring medium‑term Pharma revenue and margin expansion.
Roche Holding Ltd News
RO FAQ
What was Roche Holding Ltd’s price range in the past 12 months?
Roche Holding Ltd lowest stock price was CHF256.40 and its highest was CHF383.00 in the past 12 months.
What is Roche Holding Ltd’s market cap?
Roche Holding Ltd’s market cap is CHF281.86B.
When is Roche Holding Ltd’s upcoming earnings report date?
Roche Holding Ltd’s upcoming earnings report date is Feb 04, 2027 which is in 184 days.
How were Roche Holding Ltd’s earnings last quarter?
Roche Holding Ltd released its earnings results on Jul 23, 2026. The company reported CHF10.85 earnings per share for the quarter, beating the consensus estimate of CHF10.33 by CHF0.52.
Is Roche Holding Ltd overvalued?
According to Wall Street analysts Roche Holding Ltd’s price is currently Overvalued.
Does Roche Holding Ltd pay dividends?
Roche Holding Ltd pays a Annually dividend of CHF10.799 which represents an annual dividend yield of 3.01%. See more information on Roche Holding Ltd dividends here
What is Roche Holding Ltd’s EPS estimate?
Roche Holding Ltd’s EPS estimate is 9.65.
How many shares outstanding does Roche Holding Ltd have?
Roche Holding Ltd has 106,691,000 shares outstanding.
What happened to Roche Holding Ltd’s price movement after its last earnings report?
Roche Holding Ltd reported an EPS of CHF10.85 in its last earnings report, beating expectations of CHF10.33. Following the earnings report the stock price went up 5.148%.
Which hedge fund is a major shareholder of Roche Holding Ltd?
Currently, no hedge funds are holding shares in CH:RO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding Ltd
Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international markets. Its pharmaceutical segment develops and supplies treatments for a wide spectrum of medical conditions, encompassing oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments, as well as specific therapies for anemia, dermatology, hemophilia, inflammatory and autoimmune conditions, and transplant patients. On the diagnostic front, Roche provides in vitro tests designed to identify various diseases like cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, in addition to supplying crucial diagnostic instruments and reagents. The company was founded in Basel, Switzerland, in 1896.